Outcomes for patients with hematologic malignancy infected with COVID-19 have not been
aggregated. The objective of this study was to perform a systematic review and meta …

Background This study applies an umbrella review approach to summarise the global
evidence on the risk of severe COVID-19 outcomes in patients with pre-existing health …

Abstract Background and Aims Atezolizumab plus bevacizumab (AtezoBev) is the standard
of care for first‐line treatment of unresectable HCC. No evidence exists as to its use in …

Background Patients with cancer may be at high risk of adverse outcomes from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of …

Patients with cancer have been disproportionately affected by the COVID-19 pandemic. This
effect has included the adverse outcomes in patients with cancer who develop COVID-19 …

Introduction: COVID-19 presents benign forms in young patients who frequently present with
anosmia. Infants are rarely infected, while severe forms occur in patients over 65 years of …

Published series on COVID-19 support the notion that patients with cancer are a particularly
vulnerable population. There is a confluence of risk factors between cancer and COVID-19 …

Importance SARS-CoV-2 infection has been associated with more severe disease and
death in patients with cancer. However, the implications of certain tumor types, treatments …

Summary Background The omicron (B. 1.1. 529) variant of SARS-CoV-2 is highly
transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due …

Background Accurate molecular diagnostic tests are necessary for confirming a diagnosis of
coronavirus disease 2019 (COVID-19). Direct detection of severe acute respiratory …